Shankar, Gopi <i>et al.</i> Application No.: 10/544,117	PATENT
Page 2	

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

- 1. (Original) An isolated population of antigen presenting cells expressing CD11c⁺, CD14⁺.
- 2. (Original) The isolated population of CD11c⁺, CD14⁺ antigen presenting cells according to claim 1, wherein the antigen presenting cells are dendritic cells.
- 3. (Original) The isolated cell population according to claim 2, wherein the population is enriched for the CD11c⁺, CD14⁺ dendritic cells.
- 4. (Original) The isolated dendritic cell population according to claim 2, wherein the dendritic cell population is substantially enriched for mature dendritic cells.
- 5. (Original) The isolated dendritic cell population according to claim 2, wherein the dendritic cell population is substantially enriched for immature dendritic cells.
- 6. (Original) The isolated dendritic cell population according to claim 2, further comprising a predetermined antigen.
- 7. (Original) The isolated dendritic cell population according to claim 6, wherein the predetermined antigen is a tumor-specific antigen, a tumor associated antigen, a bacterial antigen, or a viral antigen.
- 8. (Original) The isolated dendritic cell population according to claim 7, wherein the tumor-associated antigen is a prostate-associated antigen.
- 9. (Original) The isolated dendritic cell population according to claim 8, wherein the prostate-associated antigen is prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), or prostatic acid phosphatase (PAP).

Gopi Shankar PATENT

Application No.: 10/544,117

Page 3

10. (Original) The isolated dendritic cell population according to claim 6, wherein the predetermined antigen is an autoantigen.

- 11. (Original) The isolated dendritic cell population according to claim 2, further comprising at least one cytokine.
- 12. (Original) The isolated dendritic cell population according to claim 11, wherein the at least one cytokine is a proinflammatory cytokine.
- 13. (Currently amended) The isolated dendritic cell population according to claim 12, wherein the proinflammatory cytokine is <u>tumor necrosis factor</u> (TNF α), <u>Interleukine</u> 1 β (IL-1 β), or CD40 ligand.
- 14. (Original) The isolated dendritic cell population according to claim 11, wherein the at least one cytokine is an anti-inflammatory cytokine.
- 15. (Currently amended) The isolated dendritic cell population according to claim 14, wherein the anti-inflammatory cytokine is Interleukine 10 (IL-10), transforming growth factor β (TGF- β), or prostaglandin E_2 (PGE₂).
- 16. (Currently amended) The isolated dendritic cell population according to claim 2, further comprising an enriched population of T cells, or <u>natural killer</u> (NK) cells.
- 17. (Original) The isolated dendritic cell population according to claim 16, wherein the enriched population of T cells is a cell population comprising isolated T cells.
- 18. (Original) The isolated dendritic cell population according to claim 16, wherein the isolated population of T cells is substantially enriched for T cells.
- 19. (Original) The isolated dendritic cell population according to claim 16, wherein the dendritic cell population and the T cell population are autologous, syngeneic, or allogeneic.
- 20. (Original) The isolated dendritic cell population according to claim 16, wherein the T cell population is substantially enriched for CD4⁺ T cells.

Gopi Shankar PATENT

Application No.: 10/544,117

Page 4

21. (Original) The isolated dendritic cell population according to claim 16, wherein the T cell population is substantially enriched for CD8⁺ T cells.

- 22. (Original) The isolated dendritic cell population according to claim 16, wherein the T cell population is comprised of a mixed population of CD4⁺ and CD8⁺ T cells.
- 23. (Original) The isolated dendritic cell population according to claim 16, wherein the enriched population of NK cells is a cell population comprising isolated NK cells.
- 24. (Original) The isolated dendritic cell population according to claim 16, wherein the enriched population of NK cells is a cell population substantially enriched for NK cells
- 25. (Original) The isolated dendritic cell population according to claim 16, wherein the dendritic cell population and the NK cell population are autologous, syngeneic, or allogeneic.
- 26. (Original) A composition comprising an isolated population of CD11c⁺, CD14⁺ dendritic cells and a prostate-specific membrane antigen (PSMA).
- 27. (Original) The composition according to claim 26 further comprising an isolated population of T cells or NK cells.
- 28. (Withdrawn) A method for isolating a population of CD11c⁺, CD14⁺ dendritic cells, comprising:

obtaining a population of dendritic cell precursors,

differentiating the precursors into immature or mature dendritic cells, and

selecting the population of CD11c⁺, CD14⁺ dendritic cells from the immature or mature dendritic cells.

PATENT

Gopi Shankar

Application No.: 10/544,117

Page 5

- 29. (Withdrawn) The method according to claim 28, wherein the population of dendritic cell precursors is obtained by contacting a monocytic dendritic cell precursoradhering substrate with a population of leukocytes.
- 30. (Withdrawn) The method according to claim 28, wherein the differentiation of dendritic cell precursors to immature and mature dendritic cells comprises culturing the precursors with at least one cytokine.
- 31. (Withdrawn) The method according to claim 30, wherein the at least one cytokine is GM-CSF, interleukin 4, GM-CSF and interleukin 4, interleukin 13, or interleukin 15.
- 32. (Withdrawn) The method according to claim 30, wherein the differentiation of dendritic cell precursors to immature and mature dendritic cells comprises culturing the precursors in the presence of plasma to promote the differentiation of the CD14⁺ dendritic cells.
- 33. (Withdrawn) The method according to claim 28, wherein the differentiation of dendritic cell precursors to immature and mature dendritic cells comprises culturing the precursors with a predetermined antigen.
- 34. (Withdrawn) The method according to claim 28, wherein the isolation of CD11c⁺, CD14⁺ dendritic cells from the immature and mature dendritic cells comprises

admixing the population of dendritic cell precursors with a CD14 specific probe under conditions conducive to the formation of a complex with the CD14 expressing dendritic cells;

detecting the CD14-expressing cells complexed with the CD14-specific probe; and

selecting the CD11c⁺, CD14⁺ dendritic cells.

35. (Withdrawn) The method according to claim 34, wherein the CD14-specific probe is a CD14-specific antibody.

PATENT

Gopi Shankar

Application No.: 10/544,117

Page 6

36. (Withdrawn) The method according to claim 28, wherein the selection of CD11c⁺, CD14⁺ dendritic cells from the immature and mature dendritic cells comprises affinity selection of the CD14⁺ dendritic cells with a CD14-specific probe coupled to a substrate.

- 37. (Withdrawn) The method according to claim 36, wherein the CD14-specific probe is an anti-CD14 antibody.
- 38. (Withdrawn) The method according to claim 36, wherein the substrate coupled to the CD14-specific probe is a magnetic bead.
- 39. (Original) The method according to claim 28, further comprising culturing the CD11c⁺, CD14⁺ dendritic cells to obtain an isolated population substantially enriched for mature dendritic cells.
- 40. (Withdrawn) A method for modulating an T cell response to a predetermined antigen, comprising:

obtaining an isolated population of CD11c+, CD14+ dendritic cells;

contacting the isolated population of CD11c⁺, CD14⁺ dendritic cells with a predetermined antigen; and

contacting the isolated population of CD11c⁺, CD14⁺ dendritic cells with T cells to modulate the T cell response to the predetermined antigen.

- 41. (Withdrawn) The method according to claim 40, wherein the CD11c⁺, CD14⁺ dendritic cells have been obtained from skin, spleen, bone marrow, thymus, lymph nodes, peripheral blood, or cord blood.
- 42. (Withdrawn) The method according to claim 40, wherein the CD11c⁺, CD14⁺ dendritic cells and the T cells are autologous, syngeneic, or allogeneic.

PATENT

Gopi Shankar

Application No.: 10/544,117

Page 7

- 43. (Withdrawn) The method according to claim 40, wherein the CD11c⁺, CD14⁺ dendritic cells are contacted with the T cells *in vitro* or *ex vivo*.
- 44. (Withdrawn) The method according to claim 40, wherein the predetermined antigen is a tumor-specific antigen, a tumor associated antigen, autoantigen, or a viral antigen.
- 45. (Withdrawn) The method according to claim 44, wherein the tumor-associated antigen is a prostate cancer-associated antigen.
- 46. (Withdrawn) The method according to claim 45, wherein the prostate cancer-associated antigen is prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), or prostatic acid phosphatase (PAP).
- 47. (Withdrawn) The method according to claim 40, wherein the T cells are an isolated population T cells substantially enriched for CD4⁺ T cells.
- 48. (Withdrawn) The method according to claim 40, wherein the T cells are an isolated population of T cells substantially enriched for CD8⁺ T cells.
- 49. (Withdrawn) The method according to claim 40, wherein the T cells are an isolated population of T cells comprising a mixed population of CD4⁺ and CD8⁺ T cells.